DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIRVASO

« Back to Dashboard

Clinical Trials for Mirvaso

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02249065	Mirvaso in Use Study	Completed	Galderma Laboratories, L.P.	Phase 4	This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use ofMirvaso® on the pattern and management of facial erythema of rosacea.
NCT02289352	Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea	Completed	Watson Laboratories, Inc.	Phase 3	A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
NCT02289352	Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea	Completed	Actavis Inc.	Phase 3	A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
NCT02616250	MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.	Active, not recruiting	Galderma	Phase 4	The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.

Clinical Trial Conditions for Mirvaso

Condition Name

Condition Name for Mirvaso
Intervention	Trials
Rosacea	5
Chronic Persistent Vascular Facial Erythema	1
Telangiectasias	1
Aldehyde Dehydrogenase Deficiency	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mirvaso
Intervention	Trials
Rosacea	6
Erythema	3
Flushing	2
Facies	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mirvaso

Trials by Country

Trials by Country for Mirvaso
Location	Trials
United States	30
Brazil	3
Canada	2
Germany	1
Denmark	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mirvaso
Location	Trials
North Carolina	4
California	4
Texas	3
Florida	3
Arkansas	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mirvaso

Clinical Trial Phase

Clinical Trial Phase for Mirvaso
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	1
Phase 2	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mirvaso
Clinical Trial Phase	Trials
Recruiting	4
Completed	3
Not yet recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mirvaso

Sponsor Name

Sponsor Name for Mirvaso
Sponsor	Trials
Wake Forest University Health Sciences	3
Galderma	2
Galderma Brasil Ltda.	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mirvaso
Sponsor	Trials
Other	9
Industry	7

Export unavailable in trial.
Subscribe for complete access.